122 related articles for article (PubMed ID: 15653211)
1. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.
Agorastos T; Vaitsi V; Pantazis K; Efstathiadis E; Vavilis D; Bontis JN
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):239-40. PubMed ID: 15653211
[TBL] [Abstract][Full Text] [Related]
2. Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Stilwill SE; Cooper BC
J Reprod Med; 2007 Oct; 52(10):979-80. PubMed ID: 17977182
[TBL] [Abstract][Full Text] [Related]
3. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Barker LC; Brand IR; Crawford SM
Curr Med Res Opin; 2009 May; 25(5):1105-9. PubMed ID: 19301987
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
5. Letrozole as primary therapy for endometrial hyperplasia in young women.
Li HZ; Chen XN; Qiao J
Int J Gynaecol Obstet; 2008 Jan; 100(1):10-2. PubMed ID: 17889878
[TBL] [Abstract][Full Text] [Related]
6. Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.
Koloszar S; Pal Z; Kereszturi A; Vajda G; Pal A; Daru J
Climacteric; 2012 Feb; 15(1):93-4. PubMed ID: 22132829
[TBL] [Abstract][Full Text] [Related]
7. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.
Chlebowski RT
Breast J; 2013; 19(5):552-4. PubMed ID: 23941577
[No Abstract] [Full Text] [Related]
9. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
10. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
[TBL] [Abstract][Full Text] [Related]
12. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
[TBL] [Abstract][Full Text] [Related]
13. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
14. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Oberguggenberger A; Meraner V; Sztankay M; Beer B; Weigel G; Oberacher H; Kemmler G; Czech T; Holzner B; Wildt L; Sperner-Unterweger B; Daniaux M; Hubalek M
BMC Cancer; 2017 Mar; 17(1):226. PubMed ID: 28351392
[TBL] [Abstract][Full Text] [Related]
15. Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
Tabatabaie A; Karimi Zarchi M; Dehghani-Tafti M; Miratashi-Yazdi A; Teimoori S; Dehghani A
Eur J Gynaecol Oncol; 2013; 34(6):552-5. PubMed ID: 24601050
[TBL] [Abstract][Full Text] [Related]
16. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Kyvernitakis I; Knöll D; Struck M; Hars O; Bauer T; Hadji P
J Cancer Res Clin Oncol; 2014 Jan; 140(1):159-66. PubMed ID: 24292402
[TBL] [Abstract][Full Text] [Related]
17. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Nabholtz JM
Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
19. Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥11 mm: A systematic review and meta-analysis.
Alcázar JL; Bonilla L; Marucco J; Padilla AI; Chacón E; Manzour N; Salas A
J Clin Ultrasound; 2018 Nov; 46(9):565-570. PubMed ID: 30113073
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
